Evidence map›Paper›PMID 31709279›Full record

ArticleRegenerative therapy2019

Increase of gremlin 2 with age in human adipose-derived stromal/stem cells and its inhibitory effect on adipogenesis.

Mika Kawagishi-Hotta, Seiji Hasegawa, Toshio Igarashi, Yasushi Date, Yoshie Ishii, Yu Inoue, Yuichi Hasebe, Takaaki Yamada, Masaru Arima, Yohei Iwata and 4 more

Open access · goldAbstract read
In one paragraph

Article in Regenerative therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Generation of cardiomyocytes from human-induced pluripotent stem cells resembling atrial cells with ability to respond to adrenoceptor agonists.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Mika Kawagishi-HottaResearch Laboratories, Nippon Menard Cosmetic Co., Ltd, Japan.
Seiji HasegawaResearch Laboratories, Nippon Menard Cosmetic Co., Ltd, Japan.
Toshio IgarashiResearch Laboratories, Nippon Menard Cosmetic Co., Ltd, Japan.
Yasushi DateResearch Laboratories, Nippon Menard Cosmetic Co., Ltd, Japan.
Yoshie IshiiResearch Laboratories, Nippon Menard Cosmetic Co., Ltd, Japan.
Yu InoueResearch Laboratories, Nippon Menard Cosmetic Co., Ltd, Japan.
Yuichi HasebeResearch Laboratories, Nippon Menard Cosmetic Co., Ltd, Japan.
Takaaki YamadaResearch Laboratories, Nippon Menard Cosmetic Co., Ltd, Japan.
Masaru ArimaDepartment of Dermatology, Fujita Health University School of Medicine, Japan.
Yohei IwataDepartment of Dermatology, Fujita Health University School of Medicine, Japan.
Tsukane KobayashiDepartment of Dermatology, Fujita Health University School of Medicine, Japan.
Satoru NakataResearch Laboratories, Nippon Menard Cosmetic Co., Ltd, Japan.
Kazumitsu SugiuraDepartment of Dermatology, Fujita Health University School of Medicine, Japan.
Hirohiko AkamatsuDepartment of Applied Cell and Regenerative Medicine, Fujita Health University School of Medicine, Japan.
Fujita Health University · JPNagoya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdipose-derived stromal/stem cells (ASCs) have attracted attention as a promising material for regenerative medicine. Previously, we reported an age-related decrease in the adipogenic potential of ASCs from human subjects and found that the individual difference in this potential increased with age, although the mechanisms remain unclear. Recently, other groups demonstrated that a secreted antagonist of bone morphogenetic protein (BMP) signaling, Gremlin 2 (GREM2), inhibits the differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) into osteoblasts and the adipogenesis of 3T3-L1 cell. Here, we examined the effects of GREM2 on the differentiation of ASCs into adipocytes.

methodsTo examine changes in GREM2 expression levels with age, immunohistochemistry was performed on subcutaneous adipose tissues from subjects 12-97 years of age. Next, GREM2 gene expression levels in ASCs collected from subjects 5-90 years of age were examined by RT-PCR, and the change with age and correlation between the expression level and the adipogenic potential of ASCs were analyzed. In addition, to assess whether GREM2 affects adipogenesis, ASCs (purchased from a vendor) were cultured to induce adipogenesis with recombinant GREM2 protein, and siRNA-induced GREM2 knockdown experiment was also performed using aged ASCs.

resultsIn adipose tissues, GREM2 expression was observed in cells, including ASCs, but not in mature adipocytes, and the expression level per cell increased with age. GREM2 expression levels in ASCs cultured in vitro also increased with age, and the individual differences in the level increased with age. Of note, partial correlation analysis controlled for age revealed that the adipogenic potential of ASCs and the GREM2 gene expression level were negatively correlated. Furthermore, based on a GREM2 addition experiment, GREM2 has inhibitory effects on the adipogenesis of ASCs through activation of Wnt/β-catenin signaling. On the other hand, GREM2 knockdown in aged ASCs promoted adipogenesis.

conclusionsThe GREM2 expression level was confirmed to play a role in the age-related decrease in adipogenic potential observed in ASCs isolated from adipose tissues as well as in the enhancement of the individual difference, which increased with age. GREM2 in adipose tissues increased with age, which suggested that GREM2 functions as an inhibitory factor of adipogenesis in ASCs.

Indexed as

Adipogenic differentiationAdipose-derived stromal/stem stem cellsAgingDAPI, 4′,6-diamidino-2-phenylindoleFGF, fibroblast growth factorGREM2GREM2 knockdownHE, hematoxylin eosinIndividual differencesPBS, phosphate buffered SolutionPFA, paraformaldehydeTGF-β, transforming growth factor beta

Identifiers

PMID31709279
PMCPMC6831850
OpenAlexW2981357708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.